Novosevena 1 Mg. 2 Mg & 5 Mg 1 mg. 2 mg and 5 mg Powder and solvent for solution for injection
PDF Leaflet Revision Date: 08 November 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of bleeding in patients with haemophilia and other bleeding disorders.
Dosage (summary)
Initial dose: 90 u03bcg/kg IV; repeat as needed based on bleeding severity.
Onset of Action / Duration
Onset: Immediate, Duration: Varies based on clinical response.
Special Populations
- Paediatric patients
- Elderly patients
Pregnancy & Breastfeeding
Safety in pregnancy not established; caution advised. Unknown if excreted in breast milk.
Key Drug Interactions
- Avoid simultaneous use with prothrombin complex concentrates
- Limited data on anti-fibrinolytics
Contraindications
- Hypersensitivity to eptacog alfa or excipients
- History of thromboembolic events
Common side effects
- Pyrexia
- Rash
- Thromboembolic events
Counselling Points
- Administer under medical supervision
- Home treatment limited to 24 hours
- Report any signs of allergic reactions
Serious warnings
- Risk of thrombotic events in certain conditions
- Monitor for hypersensitivity reactions
Important Disclaimer
The Novosevena 1 Mg. 2 Mg & 5 Mg 1 mg. 2 mg and 5 mg Powder and solvent for solution for injection professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
